Forgiveness of INSTI-Containing Regimens at Drug Concentrations Simulating Variable Adherence

Anti-HIV Agents / pharmacology Emtricitabine / therapeutic use Forgiveness HIV Infections / drug therapy Heterocyclic Compounds, 3-Ring / therapeutic use Humans Integrases Lamivudine / therapeutic use Pyridones / therapeutic use
bictegravir forgiveness resistance

Journal

Antimicrobial agents and chemotherapy
ISSN: 1098-6596
Titre abrégé: Antimicrob Agents Chemother
Pays: United States
ID NLM: 0315061

Informations de publication

Date de publication:
17 05 2022
Historique:
pubmed: 8 4 2022
medline: 20 5 2022
entrez: 7 4 2022
Statut: ppublish

Résumé

The integrase strand transfer inhibitor (INSTI)-based regimens bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF), dolutegravir (DTG)+FTC/TAF, DTG/lamivudine (3TC), and DTG/rilpivirine (RPV) are all approved for treatment of HIV-infected patients, with various limitations. Here, time to

Identifiants

DOI: 10.1128/aac.02038-21 PMID: 35389236 PMC: PMC9112893
pubmed: 35389236
doi: 10.1128/aac.02038-21
pmc: PMC9112893
doi:

Substances chimiques

Anti-HIV Agents 0
Heterocyclic Compounds, 3-Ring 0
Pyridones 0
Lamivudine 2T8Q726O95
Integrases EC 2.7.7.-
Emtricitabine G70B4ETF4S

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0203821

Références

Antivir Ther. 2017;22(2):169-172
pubmed: 27588613
Antimicrob Agents Chemother. 2015 Oct;59(10):6080-6
pubmed: 26195515
J Acquir Immune Defic Syndr. 2015 Dec 15;70(5):515-9
pubmed: 26262777
Infect Disord Drug Targets. 2011 Apr;11(2):167-74
pubmed: 21406048
Clin Infect Dis. 2005 Jan 1;40(1):158-63
pubmed: 15614706
Lancet. 2014 Nov 29;384(9958):1942-51
pubmed: 25103176
PLoS Genet. 2014 Jan;10(1):e1004000
pubmed: 24465214
Clin Infect Dis. 2014 Dec 15;59(12):1666-74
pubmed: 25266287
Antimicrob Agents Chemother. 2005 May;49(5):1898-906
pubmed: 15855512
J Acquir Immune Defic Syndr. 2020 Nov 1;85(3):325-330
pubmed: 32675772
Open Forum Infect Dis. 2018 Dec 10;6(1):ofy332
pubmed: 30631792
PLoS One. 2017 Feb 9;12(2):e0169948
pubmed: 28182625
Antimicrob Agents Chemother. 1993 Apr;37(4):875-81
pubmed: 7684216
PLoS One. 2012;7(7):e40514
pubmed: 22815755
Clin Infect Dis. 2020 Nov 5;71(8):1920-1929
pubmed: 31905383
Lancet HIV. 2019 Sep;6(9):e576-e587
pubmed: 31307948
Antimicrob Agents Chemother. 2020 Aug 20;64(9):
pubmed: 32601157
J Acquir Immune Defic Syndr. 2021 Mar 1;86(3):369-377
pubmed: 33196554
N Engl J Med. 2019 Aug 29;381(9):887-889
pubmed: 31461601
AIDS. 2017 Jun 19;31(10):1425-1434
pubmed: 28375875
Science. 2020 Feb 14;367(6479):806-810
pubmed: 32001525
Patient Prefer Adherence. 2019 Apr 03;13:475-490
pubmed: 31040651
Open Forum Infect Dis. 2020 Jun 02;7(6):ofaa202
pubmed: 32587877
Lancet. 2019 Jan 12;393(10167):143-155
pubmed: 30420123
Clin Infect Dis. 2005 Feb 15;40(4):601-3
pubmed: 15712084
J Viral Hepat. 2011 May;18(5):338-48
pubmed: 20456634
Clin Infect Dis. 2006 Oct 1;43(7):942-4
pubmed: 16941381
Antimicrob Agents Chemother. 2004 Jan;48(1):176-82
pubmed: 14693537
Clin Infect Dis. 2018 Aug 16;67(5):791-794
pubmed: 29933437
J Acquir Immune Defic Syndr. 2007 May 1;45(1):4-8
pubmed: 17460469
Antiviral Res. 2020 Jul;179:104717
pubmed: 31982483
JAMA. 2020 Oct 27;324(16):1651-1669
pubmed: 33052386
Cold Spring Harb Perspect Med. 2011 Sep;1(1):a007096
pubmed: 22229121
J Antimicrob Chemother. 2008 Apr;61(4):769-73
pubmed: 18256112
Lancet Infect Dis. 2014 Jul;14(7):572-80
pubmed: 24783988
Antimicrob Agents Chemother. 2021 Mar 1;:
pubmed: 33649107
J Antimicrob Chemother. 2011 Oct;66(10):2346-9
pubmed: 21750100
Infect Dis Clin North Am. 2019 Sep;33(3):707-742
pubmed: 31255384
Proc Natl Acad Sci U S A. 2014 Feb 11;111(6):2307-12
pubmed: 24469825
Ann Pharmacother. 2018 Aug;52(8):740-746
pubmed: 29482352
Retrovirology. 2018 May 16;15(1):37
pubmed: 29769116
Drugs. 2002;62(2):245-53
pubmed: 11817971
Antimicrob Agents Chemother. 2012 Mar;56(3):1427-33
pubmed: 22183172
Lancet. 2013 Aug 24;382(9893):700-8
pubmed: 23830355
Clin Infect Dis. 2018 May 17;66(11):1689-1697
pubmed: 29253097
Lancet. 2018 Mar 3;391(10123):839-849
pubmed: 29310899
AIDS Rev. 2018;20(4):179-186
pubmed: 30548024
Hepatology. 2015 Jan;61(1):56-65
pubmed: 25123381
Antivir Ther. 2016;21(6):481-488
pubmed: 26866979
J Biol Chem. 1988 Apr 25;263(12):5870-5
pubmed: 3258602
PLoS One. 2013 Dec 05;8(12):e67259
pubmed: 24339861
Proc Natl Acad Sci U S A. 1993 Jun 15;90(12):5653-6
pubmed: 7685907
J Virol. 2012 Mar;86(5):2696-705
pubmed: 22205735
Lancet HIV. 2018 Jul;5(7):e347-e356
pubmed: 29925490
J Antimicrob Chemother. 2018 Jul 1;73(7):1965-1971
pubmed: 29608685
Retrovirology. 2018 Aug 17;15(1):56
pubmed: 30119633
Antimicrob Agents Chemother. 2016 Nov 21;60(12):7086-7097
pubmed: 27645238
Antimicrob Agents Chemother. 2011 Feb;55(2):813-21
pubmed: 21115794
Lancet HIV. 2018 Jul;5(7):e357-e365
pubmed: 29925489
Antimicrob Agents Chemother. 1997 Dec;41(12):2781-5
pubmed: 9420060
Retrovirology. 2013 Feb 22;10:22
pubmed: 23432922
AIDS Res Hum Retroviruses. 2016 Dec;32(12):1237-1247
pubmed: 27356854
Science. 1985 Aug 9;229(4713):563-6
pubmed: 2992081
Open Forum Infect Dis. 2021 Jun 04;8(6):ofab297
pubmed: 34189182

Auteurs

Rima K Acosta (RK)

Gilead Sciences, Inc., Foster City, California, USA.
ORCID: 0000-0002-0255-9487

Michelle L D'Antoni (ML)

Gilead Sciences, Inc., Foster City, California, USA.

Andrew Mulato (A)

Gilead Sciences, Inc., Foster City, California, USA.

Stephen R Yant (SR)

Gilead Sciences, Inc., Foster City, California, USA.

Tomas Cihlar (T)

Gilead Sciences, Inc., Foster City, California, USA.

Kirsten L White (KL)

Gilead Sciences, Inc., Foster City, California, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antiviraux › Antirétroviraux › Agents antiVIH › Forgiveness of INSTI-Containing Regimens at...
questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Nucléosides › Nucléosides pyrimidiques › Désoxycytidine › Emtricitabine › Forgiveness of INSTI-Containing Regimens at...
questionsmedicales.fr › Comportement et mécanismes comportementaux › Relations interpersonnelles › Pardon › Forgiveness of INSTI-Containing Regimens at...
questionsmedicales.fr › Maladies du système immunitaire › Déficits immunitaires › Infections à VIH › Forgiveness of INSTI-Containing Regimens at...
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérocycliques 3 noyaux › Forgiveness of INSTI-Containing Regimens at...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Forgiveness of INSTI-Containing Regimens at...
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Recombinases › Integrases › Forgiveness of INSTI-Containing Regimens at...
questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Nucléosides › Nucléosides pyrimidiques › Désoxycytidine › Zalcitabine › Lamivudine › Forgiveness of INSTI-Containing Regimens at...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pyridines › Pyridones › Forgiveness of INSTI-Containing Regimens at...